Patents Issued in May 2, 2024
  • COMPOSITIONS AND METHODS FOR TREATING NON-TUBERCULOUS MYCOBACTERIAL INFECTIONS
    Publication number: 20240139148
    Abstract: The present disclosure provides compositions and methods related to the treatment of non-tuberculous mycobacterial infections in a subject. In particular, the present disclosure provides compositions comprising an anti-malarial agent and associated methods of treating and/or preventing a non-tuberculous mycobacterial infection in a subject using the composition.
    Type: Application
    Filed: June 10, 2022
    Publication date: May 2, 2024
    Inventors: Mary Jackson, Juan Belardinelli
  • THERAPEUTIC USES OF UROLITHIN DERIVATIVES
    Publication number: 20240139149
    Abstract: Disclosed are methods for treating a neuromuscular disorder, muscle disorder, heart disease, pulmonary fibrosis, liver disease, inflammatory bowel disease, or cancer. Also disclosed is a method of enhancing cancer immunotherapy.
    Type: Application
    Filed: July 26, 2023
    Publication date: May 2, 2024
    Inventors: Penelope Andreux, Klaus Andreas Dugi, Christopher L. Rinsch, Florian Greten, Dominic Denk
  • METHODS AND COMPOSITIONS SUITABLE FOR THE TREATMENT OF ACNE
    Publication number: 20240139150
    Abstract: Provided are compositions suitable for treating acne, disrupting a biofilm, and/or killing bacteria contained in a biofilm. Certain compositions comprise a. about 0.1 wt. % to about 7.5 wt. % glycolic acid; b. about 0.1 wt. % to about 5 wt. % gluconolactone; c. about 0.1 wt. % to about 5 wt. % mandelic acid d. a glycol; e. a salt-tolerant thickening polymer, wherein the total amount of glycolic acid, gluconolactone and mandelic acid is less than about 15 wt. % of the total composition.
    Type: Application
    Filed: January 12, 2024
    Publication date: May 2, 2024
    Inventors: Aliaksandr Zhuk, Anthony Geonnotti, Dara Miller, Jennifer Li
  • COMPOSITION INCLUDING DECURSINOL AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING SMOOTH MUSCLE CELL PROLIFERATIVE DISEASES
    Publication number: 20240139151
    Abstract: The present invention relates to a composition including decursinol as an active ingredient for preventing or treating angina, arteriosclerosis, cerebral infarction, and hypertension. Poorly soluble decursinol was found to improve angina, arteriosclerosis, cerebral infarction, prostate hypertrophy, and diabetic hypertension by inhibiting the overgrowth of vascular endothelial cells, and is expected to be usable in the development of a composition for preventing or treating angina, arteriosclerosis, cerebral infarction, prostate hypertrophy, and diabetic hypertension.
    Type: Application
    Filed: January 11, 2022
    Publication date: May 2, 2024
    Applicant: KYUNGSUNG UNIVERSITY INDUSTRY COOPERATION FOUNDATION
    Inventors: Jae Seon KANG, Hyung Hoi KIM, Jae Sung PYO, Seong Jae LEE, Ye Jin HWANG, Hyeong Soo KIM, Jae Ki CHOI
  • HBV INHIBITOR AND ITS USE
    Publication number: 20240139152
    Abstract: The present invention provides anti-HBV compounds, pharmaceutically acceptable compounds or stereoisomers thereof, and preparation methods and uses for treating, eradicating or inhibiting HBV infection or for alleviating liver injury caused by HBV infection, and so on.
    Type: Application
    Filed: November 17, 2023
    Publication date: May 2, 2024
    Applicant: XI'AN XINTONG PHARMACEUTICAL RESEARCH CO., LTD.
    Inventors: Weibo GUO, Dengke ZHANG, Weili JIN, Mingzhe JI, Yanxia ZHANG
  • Inhibition of Endothelial ETS Family Transcription Factors Promotes Flow-Dependent Ocular Vessel Regression
    Publication number: 20240139153
    Abstract: The present invention includes a method of inducing vascular regression in poorly perfused blood vessels in a subject comprising providing the subject with an effective amount of an inhibitor of an Endothelial ETS Family Transcription Factor. The compounds of the present invention are used in the treatment of retinopathy of prematurity (ROP), diabetic retinopathy (DR), or vascular malformations.
    Type: Application
    Filed: September 15, 2021
    Publication date: May 2, 2024
    Inventors: Christopher Schafer, Courtney Griffin
  • Methods of Reducing Risk of Prostate Cancer Progression
    Publication number: 20240139154
    Abstract: This disclosure provides methods of reducing the risk of prostate cancer progression in patients with a histologically proven prostate cancer characterized as low or intermediate risk for which no other treatment for prostate cancer is indicated. The method comprises administering enzalutamide as a monotherapy in an amount and for a period of time clinically proven effective in reducing the risk of prostate cancer progression in a control population of patients under active surveillance and having histologically proven prostate cancers characterized as low or intermediate risk for which no other treatment for prostate cancer is indicated.
    Type: Application
    Filed: February 28, 2022
    Publication date: May 2, 2024
    Inventors: John Hairston, Bruce Brown
  • COMPOUNDS FOR TREATING TNBC
    Publication number: 20240139155
    Abstract: There is provided tinostamustine or a pharmaceutically acceptable salt thereof for use in the treatment of triple negative breast cancer (TNBC) to a patient in need thereof.
    Type: Application
    Filed: September 12, 2023
    Publication date: May 2, 2024
    Applicant: Purdue Pharma L.P.
    Inventor: Thomas Jorg Mehrling
  • COMBINATION TREATING PROSTATE CANCER, PHARMACEUTICAL COMPOSITION AND TREATMENT METHOD
    Publication number: 20240139156
    Abstract: Disclosed are a combination treating prostate cancer, a pharmaceutical composition and a treatment method. The combination includes one of a benzoheterocyclic compound as shown in formula (I), a pharmaceutically acceptable salt thereof, a solvate thereof, a crystalline form thereof, a co-crystal thereof, a stereoisomer thereof, an isotope compound thereof, a metabolite thereof and a prodrug thereof, and an androgen receptor pathway modulator. The combination, the pharmaceutical composition thereof and the treatment method inhibit prostate cancer in a more effective manner.
    Type: Application
    Filed: January 5, 2024
    Publication date: May 2, 2024
    Inventors: Chuansheng GE, Baisong LIAO, Wen-Cherng LEE
  • Novel Tubulin Polymerization Inhibitor for Cancer Therapy
    Publication number: 20240139157
    Abstract: Provided herein is a compound and method for treating cancer cells. The method comprises administering cancer cells with a compound having the chemical structure of 2-{4-[4-methoxy-3-(trifluoromethyl)phenyl]-1H-pyrazol-1-yl}-N-(2-methyl-2H-1,2,3-triazol-4-yl)acetamide to induce apoptosis of the cancer cells and inhibit tubulin polymerization.
    Type: Application
    Filed: October 27, 2023
    Publication date: May 2, 2024
    Inventors: Renato J. Aguilera, Edgar A. Borrego Puerta
  • METHODS OF TREATING PULMONARY DISEASES AND DISORDERS
    Publication number: 20240139158
    Abstract: The present disclosure features disclosed method of treating disorders such as COPD, bronchitis and/or asthma using disclosed compounds, optionally together with one or more additional active agents. Contemplated methods include administrating orally or by inhalation to a patient one or more disclosed compounds.
    Type: Application
    Filed: December 15, 2023
    Publication date: May 2, 2024
    Inventors: John Miller, Cecilia M. Bastos, Benito Munoz
  • METHODS AND COMPOSITIONS FOR INCREASING THE EFFECTIVENESS OF ANTIVIRAL AGENTS
    Publication number: 20240139159
    Abstract: Compositions and method of the present invention comprise novel formulations for increasing the effectiveness of antiviral agents and for preventing and treating symptoms associated with the common cold and viral infections. The present invention is directed to treating symptoms resulting from viral infections and diseases associated with Picomaviridae, Coronaviridae, Orthomyxoviridae, Paramyxovirinae, Reoviridae, and Adenoviridae. The novel formulations provided herein improve the therapeutic ratio of antiviral agents such as pleconaril.
    Type: Application
    Filed: January 12, 2024
    Publication date: May 2, 2024
    Inventors: Anand Gumaste, David A. Byron
  • PHARMACEUTICAL COMBINATION COMPRISING A SELECTIVE S1P1 RECEPTOR AGONIST
    Publication number: 20240139160
    Abstract: The present invention relates to a pharmaceutical combination comprising a first active ingredient which is (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]propylimino)-3-o-tolyl-thiazolidin-4-one or a pharmaceutically acceptable salt thereof and a second active ingredient which is selected from the group consisting of methyl fumarate, dimethyl fumarate, (N,N-diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, and 2-(2,5-dioxopyrrolidin-1-yl)ethyl methyl (2E)but-2-ene-1,4-dioate, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: May 11, 2023
    Publication date: May 2, 2024
    Inventors: Martine CLOZEL, Luca PIALI
  • PHARMACEUTICAL COMBINATION COMPRISING PONESIMOD
    Publication number: 20240139161
    Abstract: The present invention relates to a pharmaceutical combination comprising a first active ingredient which is ponesimod and a second active ingredient which is selected from the group consisting of teriflunomide and leflunomide.
    Type: Application
    Filed: June 27, 2023
    Publication date: May 2, 2024
    Inventors: Martine Clozel, Laetitia Pouzol
  • Benzophenanthridine Alkaloids and Their Methods of Use
    Publication number: 20240139162
    Abstract: Described herein are compounds that can arrest mitotic cells and their use in the treatment of disorders such as cancers.
    Type: Application
    Filed: October 16, 2020
    Publication date: May 2, 2024
    Inventors: Dun Yang, Jing Zhang, Shenqiu Zhang, Jinhua Li, Qiong Shi
  • MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS
    Publication number: 20240139163
    Abstract: The invention relates to modulators of Embryonic Ectoderm Development (EED) and/or Polycomb Repressive Complex 2 (PRC2) useful in the treatment of disorders and diseases associated with EEC and PRC2, being macrocyclic azolopyridine derivatives and compositions thereof of Formula I: or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, enantiomer, isomer, or tautomer thereof, wherein X1, X2, X3, A1, A2, Y, R1, R2, R3, and R4 are as described herein.
    Type: Application
    Filed: December 20, 2022
    Publication date: May 2, 2024
    Inventors: Ivan Viktorovich Efremov, Steven Kazmirski, Qingyi Li, Lorin A. Thompson, III, Owen Brendan Wallace, Shawn Donald Johnstone, Feng Zhou, Peter Rahl
  • RAPAMYCIN ANALOGS AND USES THEREOF
    Publication number: 20240139164
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: November 1, 2023
    Publication date: May 2, 2024
    Inventors: David John O'NEILL, Eddine SAIAH, Seong Woo Anthony KANG
  • METHODS AND COMPOSITIONS FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE
    Publication number: 20240139165
    Abstract: The invention provides novel pharmaceutical compositions of berberine or a derivative or analog of berberine, or a salt thereof, in combination with one or more omega-3 fatty acids or esters thereof, and methods of their use in treating inflammatory bowel disease.
    Type: Application
    Filed: November 7, 2023
    Publication date: May 2, 2024
    Inventor: Liping LIU
  • OPHTHALMIC COMPOSITIONS FOR PRESBYOPIA
    Publication number: 20240139166
    Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition comprises a low concentration of an ophthalmic agent for treatment of presbyopia. Further disclosed herein is an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water.
    Type: Application
    Filed: February 3, 2022
    Publication date: May 2, 2024
    Inventors: Gregory I. OSTROW, Kenneth J. WIDDER, David S. BAKER
  • LYSOSOME-ASSOCIATED MEMBRANE PROTEIN TARGETING COMPOUNDS AND USES THEREOF
    Publication number: 20240139167
    Abstract: Disclosed herein is a polypeptide including a pharmaceutical composition for use in prevention or treatment of a disease or a disorder associated with lysosomal storage and an autophagy-misregulation associated disease. Further provided are agents that bind a region of an N-terminal domain of a lysosomal-associated membrane protein 1 (LAMP-1), and methods for treating or preventing development of a disease or a disorder associated with lysosomal storage, polyglucosan accumulation or abnormal glycogen accumulation and autophagy-misregulation in a subject in need thereof.
    Type: Application
    Filed: February 16, 2022
    Publication date: May 2, 2024
    Inventors: Or KAKHLON, Miguel Enrique WEIL
  • ORAL PHARMACEUTICAL COMPOSITIONS OF DABIGATRAN ETEXILATE
    Publication number: 20240139168
    Abstract: Compositions comprising a mixture of at least two types of particles wherein a) the first type of particles comprise dabigatran etexilate in the form of the free base or in the form of pharmaceutically acceptable salts, polymorphs, solvates or hydrates thereof; and b) the second type of particles comprise at least one pharmaceutically acceptable organic acid, use of said compositions in the reduction of the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation and/or in the prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery and processes for the preparation of said compositions.
    Type: Application
    Filed: July 21, 2023
    Publication date: May 2, 2024
    Applicant: Breckenridge Pharmaceutical, Inc.
    Inventors: Pratibha S. PILGAONKAR, Maharukh T. RUSTOMJEE, Anilkumar S. GANDHI
  • METHODS AND COMPOSITIONS FOR TREATING AGITATION
    Publication number: 20240139169
    Abstract: The present disclosure relates to the treatment of agitation caused by noradrenergic hyperarousal in an agitated subject. The present disclosure provides oromucosal dosage forms comprising effective amounts of latrepirdine either alone or in combination with dexmedetomidine or pharmaceutically acceptable salts thereof and one or more pharmaceutically acceptable carriers and/excipients. Methods of their use are also provided. The present disclosure also provides a method of treating depression by administering oromucosally a therapeutically effective amount of dexmedetomidine alone or in combination with latrepirdine.
    Type: Application
    Filed: February 25, 2022
    Publication date: May 2, 2024
    Inventors: Michael DE VIVO, Friso POSTMA, David Christian HANLEY, Vasukumar KAKUMANU, Subhendu SETH, Dinesh Kumar DHULL
  • TOPICAL FORMULATIONS OF A JAK 1/3 INHIBITOR AND METHODS OF USE THEREOF FOR TREATMENT OF ATOPIC DERMATITIS AND OTHER SKIN CONDITIONS
    Publication number: 20240139170
    Abstract: The present disclosure relates methods for treating skin disorders caused by an immune deficiency with topical formulations comprising ethyl (R)-4-((1-(2-cyanoacetyl)piperidin-3-yl)amino)-1H-pyrrolo[2,3-b]pyridine-5-carboxylate (Compound I) or pharmaceutically acceptable derivative thereof. In particular, the topical formulations described herein may be used to treat atopic dermatitis, alopecia areata, or vitiligo.
    Type: Application
    Filed: February 18, 2022
    Publication date: May 2, 2024
    Inventors: Paul CHANGELIAN, David GORDON, Francis IGNATIOUS, Walter SMITH, Steve TUCKER, Neal Stuart WALKER
  • TREATMENT AND/OR REDUCTION OF OCCURRENCE OF MIGRAINE
    Publication number: 20240139171
    Abstract: There is described a method of treating migraine in certain subjects suffering from migraine, by administration of a gepant to the subject. Also described is a method of reducing the incidence of migraine in certain subjects suffering from migraine, by administration of a gepant to the subject. Also described are methods for identifying the certain subjects. Other embodiments are also disclosed.
    Type: Application
    Filed: March 2, 2022
    Publication date: May 2, 2024
    Inventor: Mark HASLETON
  • PIPERIDINE UREA DERIVATIVES FOR CANCER THERAPY
    Publication number: 20240139172
    Abstract: Described herein are novel piperidine urea derived compounds and their pharmaceutical compositions for the treatment of cancer as a monotherapy or a combination therapy with chemotherapeutic agents and/or checkpoint inhibitors.
    Type: Application
    Filed: September 29, 2023
    Publication date: May 2, 2024
    Applicant: NeuroPn Therapeutics, Inc.
    Inventors: Ish Khanna, Sivaram Pillarisetti, Hans Marcus Malkmus, Kathrin Christin Kortschak
  • OPHTHALMIC FORMULATIONS AND USES THEREOF
    Publication number: 20240139173
    Abstract: The present invention provides a reproxalap ophthalmic solution, and methods of using the same for treating a disease or disorder such as allergic conjunctivitis.
    Type: Application
    Filed: September 12, 2023
    Publication date: May 2, 2024
    Inventors: David CLARK, Susan MACDONALD, Stephen Gitu MACHATHA, Lise Lund KJEMS
  • COMBINATION THERAPY WITH A VINCA ALKALOID N-OXIDE AND AN IMMUNE CHECKPOINT INHIBITOR
    Publication number: 20240139175
    Abstract: The present disclosure provides therapeutic methods of treating a cancer patient with a vinca alkaloide N-oxide and an immune checkpoint inhibitor.
    Type: Application
    Filed: December 23, 2021
    Publication date: May 2, 2024
    Applicant: CASCADE PRODRUG INC.
    Inventor: August J. SICK
  • METHODS OF TREATING OR PREVENTING CACHEXIA
    Publication number: 20240139176
    Abstract: A method treats or prevents cachexia by administering a therapeutic or prophylactic agent for cachexia and contains a combination of a ghrelin receptor agonist a compound having a morphinan skeleton, represented by the following compounds, or a pharmacologically acceptable acid addition salt thereof:
    Type: Application
    Filed: October 23, 2020
    Publication date: May 2, 2024
    Inventors: Yu Omori, Masashi Uchida
  • METHODS FOR PRODUCING ARIPIPRAZOLE SUSPENSION AND FREEZE-DRIED FORMULATION
    Publication number: 20240139177
    Abstract: Disclosed are a method for producing an aripiprazole suspension, wherein the aripiprazole has a mean particle size of 1 to 10 ?m, the method comprising the steps of: (a) combining bulk aripiprazole and a vehicle to form a primary suspension; (b) subjecting the primary suspension to first pulverization using e.g., a high shear pulverizing machine, a dispersion machine that applies shear force to a material to be processed, a colloid mill, an ultrasonic dispersion machine, or a high-pressure jet type emulsifying dispersion machine to form a secondary suspension; and (c) subjecting the secondary suspension to second pulverization using e.g., a high-pressure jet type emulsifying dispersion machine to form a sterile final suspension; and a method for producing a freeze-dried formulation from the aripiprazole suspension.
    Type: Application
    Filed: December 26, 2023
    Publication date: May 2, 2024
    Inventors: Shogo HIRAOKA, Takakuni MATSUDA, Junichi HATANAKA
  • METHOD FOR MANUFACTURING COMPOSITION FOR COMPOSITION FOR INCREASING COGNITIVE FUNCTION
    Publication number: 20240139178
    Abstract: Provided is a method for manufacturing a composition for increasing cognitive function.
    Type: Application
    Filed: January 5, 2024
    Publication date: May 2, 2024
    Applicant: AMYLOID SOLUTION INC.
    Inventors: Seong Muk KIM, Young Soo Kim, Ji Su Shin, Han Na Jeon, Dong Hee Lee, Hye Ju Kim
  • TRAZODONE AND TRAZODONE HYDROCHLORIDE IN PURIFIED FORM
    Publication number: 20240139179
    Abstract: A process of production of trazodone or trazodone hydrochloride that comprises: (a) preparing an organic phase comprising trazodone in at least one organic solvent; (b) preparing an aqueous phase comprising at least one basic compound; (c) mixing said aqueous phase with said organic phase; (d) heating at a temperature of at least 40° C. for at least 30 minutes; (e) recovering said trazodone; and, optionally, (f) treating said trazodone with hydrochloric acid to obtain trazodone hydrochloride. Trazodone or trazodone hydrochloride comprising less than 15 ppm of alkylating substances, and a pharmaceutical composition comprising said trazodone hydrochloride.
    Type: Application
    Filed: January 12, 2024
    Publication date: May 2, 2024
    Applicant: AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A.
    Inventors: Marcello MARCHETTI, Tommaso IACOANGELI, Giovanni Battista CIOTTOLI, Giuseppe BIONDI (Deceased)
  • METHODS FOR INDUCING PUPIL DILATION
    Publication number: 20240139181
    Abstract: The present invention provides methods for inducing rapid and significant dilation of a subject's pupils. In certain embodiments, the method comprises upregulating the alpha-1 receptors in the eye of the subject, thereby increasing sensitivity to alpha-1 agonists. In other embodiments, such upregulation is achieved through administration of at least one compound selected from the group consisting of alpha-2 selective agonists and beta adrenoreceptor antagonists for a period of time prior to the intended time of dilation. After inducing the upregulation of alpha-1 receptors through the administration of at least one compound selected from the group consisting of alpha-2 selective agonists and beta adrenoreceptor antagonists, alpha-1 agonists can be administered to induce rapid and strong pupil dilation.
    Type: Application
    Filed: May 30, 2023
    Publication date: May 2, 2024
    Inventor: Cristos IFANTIDES
  • Certain Triazolopyridines and Triazolopyrazines, Compositions Thereof and Methods of Use Therefor
    Publication number: 20240139182
    Abstract: Provided are certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor.
    Type: Application
    Filed: December 13, 2023
    Publication date: May 2, 2024
    Inventors: Wei-Guo Su, Hong Jia, Guangxiu Dai
  • COMPOUND FOR SUPPRESSING NONSENSE-MEDIATED MRNA DECAY
    Publication number: 20240139183
    Abstract: The present invention relates to a compound for inhibition of nonsense-mediated mRNA decay (hereinafter referred to as “NMD”) or a pharmaceutically acceptable salt thereof. The present invention aims to prevent or treat NMD-related disease through the NMD-inhibiting compound.
    Type: Application
    Filed: February 15, 2022
    Publication date: May 2, 2024
    Applicant: RiboTech Co., Ltd.
    Inventor: Yoon Ki KIM
  • COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF
    Publication number: 20240139185
    Abstract: The disclosure features macrocyclic compounds, alone and in combination with other therapeutic agents, as well as pharmaceutical compositions and protein complexes thereof, capable of modulating biological processes including RAS and RAS-RAF inhibition, and their uses in the treatment of cancers.
    Type: Application
    Filed: March 16, 2023
    Publication date: May 2, 2024
    Inventors: Meizhong JIN, Nicholas Perl, Anna Kohlmann, Ning Yin, Jason T. Lowe, Jae Young Ahn, Mark Joseph Mulvihill, Elena S. Koltun, Adrian L. Gill
  • METHODS OF TREATING HIV
    Publication number: 20240139186
    Abstract: The disclosure is directed to the use of rilpivirine, or a salt thereof, to treat HIV infection in pediatric subjects.
    Type: Application
    Filed: January 10, 2024
    Publication date: May 2, 2024
    Inventors: Herta Crauwels, Simon Vanveggel, Veerle Van Eygen
  • SELECTIVE HYPOTHALAMUS PERMEABLE HDAC6 INHIBITORS FOR TREATMENT OF LEPTIN-RESISTANT OBESITY
    Publication number: 20240139187
    Abstract: Formulations of HDAC6 inhibitors passing through the blood brain barrier in hypothalamus and inhibiting HDAC6 in the arctuate AgRP neurons in the hypothalamus, are effective to cause weight loss in obese individuals. These inhibitors also restore leptin sensitivity in leptin-resistant individuals.
    Type: Application
    Filed: May 26, 2023
    Publication date: May 2, 2024
    Inventors: Umut Ozcan, Ralph Mazitschek, Dongxian Guan
  • Arylamide Compounds For Treatment And Prevention Of Fungal Infections
    Publication number: 20240139188
    Abstract: The present disclosure provides methods for treating or preventing a fungal infection with one or more arylamide compounds, or pharmaceutically acceptable salts thereof, or compositions comprising the same and an additional anti-fungal agent, and pharmaceutical compositions comprising one or more arylamide compounds and at least one additional anti-fungal agent.
    Type: Application
    Filed: September 22, 2023
    Publication date: May 2, 2024
    Inventors: Gustavo H. Goldman, Thaila Fernanda dos Reis
  • N6-ADENOSINE-METHYLTRANSFERASE INHIBITORS IN CANCER TREATMENT
    Publication number: 20240139189
    Abstract: The present invention relates to N6-adenosine-methyltransferase inhibitors and to dual N6-adenosine-methyltransferase E3 ligase binders in cancer treatment.
    Type: Application
    Filed: November 10, 2023
    Publication date: May 2, 2024
    Inventors: Amedeo CAFLISCH, Aymeric DOLBOIS, Danzhi HUANG, Frantisek ZALESAK
  • NOVEL ANTIPARASITIC COMPOUNDS AND METHODS
    Publication number: 20240139190
    Abstract: Novel compounds for treating or inhibiting leishmaniasis and other parasitic protozoan diseases are disclosed herein. The compounds bind to Leishmania tubulin, induce parasite microtubule polymerization, stall Leishmania cell division, and have broad antiparasitic activity.
    Type: Application
    Filed: October 19, 2020
    Publication date: May 2, 2024
    Inventors: Dawn M. WETZEL, Imran ULLAH, Laela M. BOOSHEHRI, Joseph READY, Suraksha GAHALAWAT, Bin HU, Yesu ADDEPALLI
  • SMALL MOLECULES AS LARP1 LIGANDS
    Publication number: 20240139191
    Abstract: Disclosed are compounds and compositions that bind to the La-related protein 1 (LARP1). LARP1 has roles as both a repressor of translation and stabilizer of mRNA transcripts, and therefore functions as a molecular switch in cancer biology. LARP1 also upregulates the proliferation of RNA viruses. Accordingly, the compounds and compositions disclosed herein that bind to LARP1 may be used for treating or preventing cancer or viral infections in a subject.
    Type: Application
    Filed: December 14, 2020
    Publication date: May 2, 2024
    Inventors: Jacob D. DURRANT, Andrea Jeanne BERMAN, Kevin Christopher CASSIDY, Roni Marta LAHR
  • METHODS AND COMPOSITIONS COMPRISING A BRAF INHIBITOR AND A MEK INHIBITOR
    Publication number: 20240139192
    Abstract: The present invention is directed to the combination therapy of cancer with a BRAF inhibitor and a MEK inhibitor, as well as uses and pharmaceutical compositions thereof.
    Type: Application
    Filed: December 8, 2023
    Publication date: May 2, 2024
    Applicants: Hoffmann-La Roche Inc., Chugai Seiyaku Kabushiki Kaisha
    Inventors: Jan ECKMANN, Thomas FRIESS, Frank HERTING, Yusuke IDE, Hiroshi TANAKA, Piergiorgio Francesco Tommaso PETTAZZONI, Juergen WICHMANN
  • COMBINATION THERAPY OF KRAS INHIBITOR AND SHP2 INHIBITOR FOR TREATMENT OF CANCERS
    Publication number: 20240139193
    Abstract: Provided herein are methods of administering a KRAS G12C inhibitor in combination with a SHP2 inhibitor to a cancer subject.
    Type: Application
    Filed: October 14, 2020
    Publication date: May 2, 2024
    Inventors: Haby HENARY, James Russell LIPFORD
  • PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5-MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS
    Publication number: 20240139194
    Abstract: The present disclosure relates to compounds of the Formula (I): and pharmaceutically acceptable salts, as kinase modulators, compatible with the Type-II inhibition of kinases.
    Type: Application
    Filed: May 11, 2023
    Publication date: May 2, 2024
    Inventor: Gary A. Flynn
  • METHODS OF TREATING CHRONIC ACTIVE ANTIBODY-MEDIATED REJECTION USING BTK INHIBITORS
    Publication number: 20240139195
    Abstract: The present disclosure provides methods for treating chronic active antibody-mediated rejection (CAMR), in a subject, comprising administering to the subject a therapeutically effective amount of a BTK inhibitor, particularly (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo-[1,5-a] pyrimidine-3-carboxamide or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: January 29, 2022
    Publication date: May 2, 2024
    Inventor: Jiajun ZHOU
  • COMBINATION TREATMENTS IN DIFFICULT TO TREAT PATIENTS WITH ADVANCED AND/OR METASTATIC TROP-2 OVEREXPRESSING CANCERS
    Publication number: 20240139196
    Abstract: This invention is in the area of improved combination treatments for a select group of hard-to-treat cancer patients, including, for example, those with advanced/metastatic triple negative breast cancer (TNBC), recurrent or metastatic urothelial cancer (mUC), or a Trop-2 overexpressing cancer such as non-small cell lung cancer (NSCLC), wherein the improved combination includes the use of trilaciclib and sacituzumab govitecan, and provides increased overall survival and/or reduced toxicity.
    Type: Application
    Filed: December 22, 2023
    Publication date: May 2, 2024
    Applicant: G1 Therapeutics, Inc.
    Inventors: Andrew Beelen, Rajesh Kumar Malik, John Seung-Hoon Yi, Curt Douglas Wolfgang
  • INHIBITION OF KDM5A FOR PROMOTING ANTIGEN PRESENTATION, INCREASING CD8+ T CELL INFILTRATION AND BOOSTING ANTI-TUMOR IMMUNE RESPONSE
    Publication number: 20240139197
    Abstract: Methods of treating cancer, promoting antigen presentation, or increasing CD8+ T cell infiltration in tumors by inhibiting KDMA5 are provided.
    Type: Application
    Filed: October 10, 2023
    Publication date: May 2, 2024
    Inventor: Rugang Zhang
  • METHOD AND COMBINATION FOR TREATING TUMORS
    Publication number: 20240139198
    Abstract: The present application relates to a pharmaceutical combination comprising a phosphoinositide 3-kinase (PI3K) inhibitor and a second therapeutic agent, wherein the second therapeutic agent is an immune checkpoint inhibitor, a TGF? inhibitor, a bifunctional immune checkpoint/TGF? inhibitors or combinations thereof. The present application also provides a method of treatment comprising administering the combination, and the use of the drug combination for treating tumors.
    Type: Application
    Filed: February 9, 2022
    Publication date: May 2, 2024
    Inventors: Rongzhen LU, Zhihong CHEN
  • USE OF ADENINE IN PREPARATION OF DRUG FOR TREATING DIABETIC ULCERS
    Publication number: 20240139199
    Abstract: The present disclosure provides a use of a pharmaceutical composition including adenine and/or a pharmaceutically acceptable salt thereof in a manufacture of a medicament for treating diabetic ulcers, and the medicament can effectively accelerate and enhance wound healing of diabetic ulcers and prevent scar formation.
    Type: Application
    Filed: March 25, 2022
    Publication date: May 2, 2024
    Inventors: Jen-Yi Chio, Han-Min Chen, Jiun-Tsai Lin, Yi-Fang Cheng, Guang-Huar Young, Chun-Fang Huang
  • COMBINATION OF REBOXETINE AND A MUSCARINIC RECEPTOR ANTAGONIST (MRA) FOR USE IN TREATING SLEEP APNEA
    Publication number: 20240139200
    Abstract: Pharmaceutical compositions comprising reboxetine or a pharmaceutically acceptable salt thereof and a muscarinic receptor antagonist (MRA) and methods of treating sleep apnea comprising administering reboxetine or a pharmaceutically acceptable salt thereof and an MRA are described herein. In some embodiments, the MRA is oxybutynin or (R)-oxybutynin or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 3, 2022
    Publication date: May 2, 2024
    Inventors: Lawrence G. MILLER, Ronald FARKAS, Luigi TARANTO-MONTEMURRO